Special attention has been paid to PDE4 inhibitors, which are potent anti-inflammatory agents that have shown encouraging results in the treatment of chronic obstructive pulmonary disease (COPD) and asthma. The gene discussed is PDE4A; the disease is chronic obstructive pulmonary disease.